These findings provide strong proof-of-principle for repurposing NCS as an HuR inhibitor, potentially offering a promising adjunctive therapy alongside current treatments to prevent renal failure associated with diabetes. The gene discussed is ELAVL1; the disease is Renal insufficiency.